Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.04. | OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 | 268 | GlobeNewswire (Europe) | LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory... ► Artikel lesen | |
09.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
02.04. | OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery | 173 | GlobeNewswire (Europe) | LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory... ► Artikel lesen | |
29.03. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
25.03. | OKYO Pharma Ltd expected to post a loss of 11 cents a share - Earnings Preview | 1 | Reuters | ||
22.03. | Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study | 3 | Benzinga.com | ||
22.03. | OKYO Pharma gains after positive results from Phase 2 dry eye disease trial | 1 | Seeking Alpha | ||
22.03. | OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 | 249 | GlobeNewswire (Europe) | Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.Conjunctival Staining improved as early as day 29 with a durable benefit... ► Artikel lesen | |
21.03. | OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial | 199 | GlobeNewswire (Europe) | -Phase 2 OK-101 efficacy data to be released March 22nd, 2024-
-KOL Event to be held on April 9th, 2024 at 12 PM ET-
LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited... ► Artikel lesen | |
20.03. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
20.03. | OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event | 175 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory... ► Artikel lesen | |
09.02. | FDA approves OKYO Pharma's IND for NCP treatment trial | 2 | Investing.com | ||
09.02. | OKYO Pharma gains on receiving FDA nod of IND for OK-101 in neuropathic corneal pain | - | Seeking Alpha | ||
09.02. | OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain | 325 | GlobeNewswire (Europe) | OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe initial... ► Artikel lesen | |
09.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
31.01. | OKYO Pharma expands Scientific Advisory Board | 2 | Investing.com | ||
31.01. | OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board | 269 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory... ► Artikel lesen | |
31.01. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
08.01. | OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease | 381 | GlobeNewswire (Europe) | Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a... ► Artikel lesen | |
05.01. | OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 | 294 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 81,20 | +0,74 % | BioNTech Aktie: Abwärtstrend hält an | Die Aktie des Mainzer Biotechnologieunternehmens BioNTech liegt aktuell bei 81,25 € und zeigt eine minimale Veränderung von 0,06% über die letzte Woche. Trotz des vergleichsweise stabilen Kursrückgangs... ► Artikel lesen | |
MEDIGENE | 1,910 | -0,52 % | PTA-News: Medigene AG: Medigene präsentiert auf folgenden wissenschaftlichen Konferenzen | DJ PTA-News: Medigene AG: Medigene präsentiert auf folgenden wissenschaftlichen Konferenzen
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/17.04.2024/12:00) - Die Medigene... ► Artikel lesen | |
CUREVAC | 2,290 | -0,61 % | CureVac Aktie: Hoffnung trotz Abwärtstrends? | CureVac-Aktien haben in der letzten Woche einen leichten Rückgang von 0,65 % hinnehmen müssen und notieren aktuell bei 2,75 €. Trotz der marginalen Erholung am Freitag um etwa 2 % bleibt das Papier... ► Artikel lesen | |
QIAGEN | 37,470 | +1,19 % | Qiagen: Aufschwung in der zweiten Jahreshälfte | Analysten der Deutschen Bank erwarten beim Jahresauftakt von Qiagen keine Überraschungen. Das Unternehmen prognostiziert einen Umsatz von rund 455 Millionen Dollar, das wäre ein Minus von rund 6 Prozent.... ► Artikel lesen | |
AMGEN | 253,05 | +0,24 % | Amgen Aktie: Hoffnungsträger Tezspire trotz Studiendämpfer | Amgen lässt mit seinen Aktivitäten rund um das vielversprechende Medikament Tezspire aufhorchen. Trotz gemischter Ergebnisse in der Phase-2-Studie zur Behandlung von COPD, hat Wells Fargo das Rating... ► Artikel lesen | |
NOVAVAX | 3,703 | -1,00 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
CRISPR THERAPEUTICS | 53,25 | +0,47 % | CRISPR Therapeutics' Options Frenzy: What You Need to Know | ||
REGENERON PHARMACEUTICALS | 837,60 | -0,43 % | Regeneron Ventures: $500 Million Fund Launch To Invest In Biotech Companies | ||
ORGANOVO | 1,038 | -0,95 % | Organovo, Inc.: Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo | SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 9,080 | -0,22 % | Pre-market Movers: Macatawa Bank, Ryvyl, WiSA Technologies, Inovio Pharmaceuticals, Mobilicom | STOCKHOLM (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.55 A.M. ET).In the Green Macatawa Bank Corporation (MCBC) is up over 38%... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,494 | +2,92 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
INFLARX | 1,260 | -2,02 % | InflaRx: Bis 2026 durchfinanziert - Verlust gestiegen | Das Biotech-Unternehmen InflaRx meldet für das Geschäftsjahr 2023 einen Anstieg des Defizits vor Zinsen und Steuern von 32,2 Millionen Euro auf 44,9 Millionen Euro. Unter dem Strich steigt der Verlust... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 19,530 | -3,56 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
BIO-GATE | 1,030 | 0,00 % | BioGate Precision Medicine Corp.: A Global Milestone in Innovative Pancreatic Cancer Therapy | Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy... ► Artikel lesen | |
VIKING THERAPEUTICS | 59,28 | -0,40 % | Viking Therapeutics (VKTX) to Report Q1 Earnings: What's in the Cards? |